Several authorities underlined that in such situations there is a significant risk of losing traceability, including inappropriate reporting of pregnancy rate and serious adverse reactions following medical application (e.g. children born with genetic diseases not reported back to the distributing tissue establishment).
Mitmed ametiasutused rõhutasid, et sellises olukorras on märkimisväärne oht jälgitavuse kaotamiseks, sealhulgas moonutatud aruandlus raseduste osakaalust ja meditsiinilise sekkumisega seotud rasketest kõrvaltoimetest (nt pärilike haigustega sündinud lastest teatamata jätmine tarnimise eest vastutavale koepangale).